Justin Bryans

Justin joined Charles River Laboratories in 2022 as Chief Scientific Officer, Discovery and in this role he works closely with a range of experts to develop CRL’s drug discovery strategy, explore opportunities with existing and prospective clients, evaluate new areas of science and technology, and develop new approaches to strengthen the CRL offering. Justin trained as a chemist at the universities of York and Oxford, the latter being as a post-doc under Professor Sir Jack Baldwin. Since then, he has gained over 30 years’ experience in drug discovery at several biotechnology and pharma companies including Parke-Davis and Pfizer.

 

Prior to joining CRL, he spent 16 years as Director of Drug Discovery at LifeArc, a UK based charity and not-for-profit organisation, where he led a team covering chemistry, biology, antibodies and diagnostics. Justin is cited as an inventor on 50 patents and has published around 40 papers. Justin holds an honorary professorship from Queen Mary University of London (QMUL) and he teaches on various aspects of drug discovery at QMUL, University College London and the Wellcome Trust. He also sits on a range of advisory committees and panels in the UK and Sweden.